Does HRT protect the heart or harm it?

The relationship between HRT and cardiovascular risk depends heavily on when therapy is started relative to menopause. Current clinical guidelines do not support using HRT for the prevention of cardiovascular disease.

How Timing Affects Cardiovascular Risk

According to current NAMS guidelines, initiating hormone therapy before age 60 or within 10 years of the final menstrual period is associated with a more favorable cardiovascular risk profile compared to later initiation. Per the WHI long-term follow-up data, women who began estrogen therapy in this earlier window showed lower rates of coronary heart disease events than those who started later. These findings support the concept of a timing-dependent effect, often referred to as the "timing hypothesis," though this does not constitute a preventive indication.

According to the WHI long-term follow-up data, the route of administration also appears relevant. Transdermal estrogen delivery — via patch, gel, or spray — maintains steadier hormone levels and avoids first-pass hepatic metabolism, which per published clinical guidelines may be associated with a lower risk of venous thromboembolism compared to oral estrogen. The clinical significance of these differences varies by individual patient factors.

When Cardiovascular Risk May Increase

Per the Endocrine Society, initiating HRT more than 10 years after menopause or after age 60 in women with established atherosclerosis carries a different risk profile. According to the WHI long-term follow-up data, women in this group who received combined estrogen-progestogen therapy showed increased rates of coronary heart disease events early in the trial period. This pattern is consistent with the hypothesis that estrogen may destabilize existing arterial plaque when vascular disease is already present.

Per FDA-approved prescribing information, estrogen therapy is contraindicated in women with a history of arterial thromboembolic disease. Women with uncontrolled hypertension or a history of stroke or blood clots require individualized assessment before any hormone therapy is considered.

Key Considerations by Patient Profile

• Earlier initiation (before age 60 or within 10 years of menopause): Per current NAMS guidelines, cardiovascular risk is generally not elevated and may be more favorable in healthy women without pre-existing vascular disease.
• Later initiation: According to ACOG, the risk-benefit balance shifts unfavorably for cardiovascular outcomes when therapy is started in older women or those with established vascular disease.
• Route of administration: Per published clinical guidelines, transdermal estrogen and micronized progesterone have a more favorable thrombotic risk profile than oral combined therapy.
• Individual history: Cholesterol levels, blood pressure, family history of cardiovascular disease, and prior clot history all substantially affect the risk assessment for any individual patient.

If a clinician and patient are considering compounded hormone preparations, the following applies: Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Per FDA-approved prescribing information, estrogen-based therapies should not be used for the prevention of cardiovascular disease. Current guidelines support HRT use for management of menopausal symptoms, not as a cardiovascular risk-reduction strategy.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history, including cardiovascular risk factors, age at menopause, time since menopause, and personal treatment goals.